CPSE:NOVO BPharmaceuticals
Novo Nordisk Patent Fight Puts Wegovy Exclusivity And Valuation In Focus
Novo Nordisk (CPSE:NOVO B) has filed a US patent lawsuit against Hims & Hers over a compounded oral semaglutide weight loss pill that used the active ingredient in Wegovy and Ozempic.
The telehealth company withdrew the product within days after regulatory pressure from the FDA and the Department of Health and Human Services.
Novo Nordisk is seeking a permanent injunction to limit copycat versions and protect its intellectual property in the obesity drug market.
Novo Nordisk, best known for...